BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, will present new findings at the American College of Gastroenterology (ACG) 2024 Annual ...
Characteristics of Patients and Prognostic Factors Across Treatment Lines in Metastatic Colorectal Cancer: An Analysis From the Aide et Recherche en Cancérologie Digestive Database A safety cohort ...
Topline results were announced from two phase 3 trials evaluating doravirine/islatravir (DOR/ISL) in adults with virologically-suppressed HIV-1 infection. The investigational therapy combines ...
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study of suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal ...
CHICAGO — Positive phase 3 trials for two drugs, telitacicept and ianalumab, showed promise for offering systemic treatment for Sjögren disease, rather than only symptom control. Findings of both ...
ORLANDO, Fla. — A second phase 2 trial with the tyrosine kinase 2 (TYK2) inhibitor deucravacitinib has met the primary efficacy endpoints for the treatment of the skin manifestations of cutaneous ...
Low dose interleukin 2 is being tested as an immunomodulatory approach in neurodegenerative diseases. It increases the number and activity of regulatory T cells (Tregs) that suppress inflammation. At ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback